Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 19\~45 years old, Healthy Adult Male Subject~* 17.5\~30.5kg/m2(BMI) and ≥ 40kg(Body Weight)~Exclusion Criteria:~* SBP ≥ 140mmHg or DBP ≥ 90mmHg

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- GLA5PR GLARS-NF1 tablet 150mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
- GLA5PR GLARS-NF1 tablet 300mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
- GLA5PR GLARS-NF1 tablet 450mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
- GLA5PR GLARS-NF1 tablet 600mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)

Based on this trial design, predict the completion outcome and termination type (if applicable).